Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B
- 1 March 2011
- journal article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 18 (7) , e217-e225
Abstract
Summary. Current guidelines recommend antiviral therapy in chronic hepatitis B (HBV) patients with significant histological disease. We aimed to compare histological fibrosis (METAVIR, ≥F2) in patients with HBV DNA ≥20 000 IU/mL vs≥2000 IU/mL and identify predictors of fibrosis. We performed prospective liver biopsies on 203 HBeAg‐negative patients in four groups: Group I (n = 55): HBV DNA ≥20 000 IU/mL and persistently elevated alanine aminotransferase (ALT) levels (PEALT; >40 U/L); Group II (n = 34): HBV DNA ≥20 000 IU/mL and persistently normal ALT (PNALT); Group III (n = 40): HBV DNA n = 74): HBV DNA P < 0.0001). Except in Group II with a trend for lower ≥F2 fibrosis (P = 0.067), there was no significant difference by using HBV DNA cut‐off 20 000 vs 2000 IU/mL. Multivariate logistic regression analysis identified study Group IV (OR, 0.0276; CI: 0.088–0.868; P = 0.0276) and milder (A0–1) necroinflammatory grade (OR, 0.135; CI: 0.063–0.287; P < 0.0001) as independent predictors of ≥F2 fibrosis. The specificity, positive and negative predictive values for PEALT in detection of ≥F2 fibrosis for viremia ≥2000 IU/mL (80%, 69% and 65%, respectively) or ≥20 000 IU/mL (86%, 73% and 63%, respectively) were similar, with a marginal gain in sensitivity (51%vs 42%, respectively). Significant fibrosis is prevalent in a large proportion of HBeAg‐negative patients with high viremia and persistently normal ALT. Lower HBV DNA cut‐offs could be adopted with marginal gains in fibrosis detection and without loss of diagnostic accuracy.Keywords
This publication has 20 references indexed in Scilit:
- Histological Disease in Asian-Americans With Chronic Hepatitis B, High Hepatitis B Virus DNA and Normal Alanine Aminotransferase LevelsAmerican Journal of Gastroenterology, 2009
- Evaluation of Liver Biopsy in Egyptian HBeAg-Negative Chronic Hepatitis B Patients at Initial Presentation: Implications for TherapyAmerican Journal of Gastroenterology, 2009
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen–negative chronic hepatitis B virus infection?Hepatology, 2008
- Factors Predictive of Significant Hepatic Fibrosis in Adults With Chronic Hepatitis B and Normal Serum ALTJournal of Clinical Gastroenterology, 2008
- Virologic and Histologic Features of Chronic Hepatitis B Virus-Infected Asymptomatic Patients With Persistently Normal ALTGastroenterology, 2008
- Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg‐negative chronic hepatitis B virus infectionJournal of Viral Hepatitis, 2008
- Hepatitis B virus DNA prediction rules for hepatitis B e antigen–negative chronic hepatitis BHepatology, 2007
- An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniquesVox Sanguinis, 2001
- Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis CHepatology, 1994